QuidelOrtho Corp (NASDAQ: QDEL)

$12.05 ▲ +0.01 (+0.08%)
As of Apr 22, 2026 03:35 PM
Sector: Healthcare Industry: Medical Devices CIK: 0001906324
Add ratio to table...

About

QuidelOrtho Corp operates as a leading provider of diagnostic solutions, specializing in the development, manufacturing, and distribution of in vitro diagnostic (IVD) products. The company serves the healthcare industry, focusing on delivering innovative diagnostic technologies that cater to both clinical laboratories and point-of-care settings. QuidelOrtho Corp's portfolio spans a wide range of diagnostic solutions, including immunoassays, molecular diagnostics, and automation systems, designed to enhance patient care and improve clinical outcomes. The...

Read more

Investment thesis

Bull case

  • The company’s labs segment has sustained double‑digit regional growth, with LATAM achieving 18% and EMEA 4% while margins improved by 900 basis points, indicating that market penetration is still strong. This regional expansion, coupled with the continued 7% full‑year growth, signals a resilient demand base that can support incremental top‑line acceleration. Moreover, the product mix shift toward higher‑margin immunoassays and the addition of the high‑sensitivity troponin I assay on the VITROS platform will gradually lift gross margin, creating a structural upside that has not yet been fully priced in. The ability to upsell these new, clinically critical assays to hospitals and laboratories further strengthens the revenue pipeline.
  • Product pipeline developments—FDA clearance of the VITROS troponin assay and the iDMTS direct antiglobulin test card—are positioned to drive sales momentum within a short lead time, as U.S. shipments are anticipated within weeks. The company’s strategic OUS partnership, which adds more than 25 assays to a menu exceeding 70, enhances its competitiveness in tender‑driven markets and opens a high‑volume opportunity that could significantly boost international revenue. Although the Lex molecular diagnostics platform will initially be dilutive, its eventual commercial success is expected to deliver high‑margin PCR testing that can offset the initial cost of the acquisition, thereby creating a long‑term positive cash flow effect. These catalysts underscore a product pipeline that aligns with evolving market demands, offering a tangible growth engine.
  • Financial metrics show a steady improvement in operating efficiency, with adjusted EBITDA projected at 23.3% in 2026—a 130 basis point lift over 2025. The company’s disciplined cost‑saving initiatives, including direct procurement and manufacturing optimization, are already delivering margin gains and are expected to intensify in the coming years. Importantly, the incremental investment in ERP and reagent rental capitalization is a short‑term expense that will mature into depreciation, freeing up cash flow and reducing future depreciation headwinds. When combined with the projected free cash flow of $120–$160 million (excluding onetime costs) and a move toward a 30% free‑cash‑flow conversion, the company is well positioned to fund growth and return capital to shareholders.
  • Capital structure management is on a clear trajectory, with net debt to adjusted EBITDA expected to drop to 3.8x in 2026 from 4.2x, bringing leverage within the target range of 2.5–3.5x. The company’s recent debt refinancing and its plans to refinance term loan B at potentially lower rates are likely to reduce interest expense further, enhancing net income and cash flow. Coupled with the planned focus on flipping reagent rental customers to cash instrument sales, these moves provide a structural benefit that can improve balance‑sheet health and free up capital for future acquisitions or share repurchases. The market may be underestimating the impact of these leverage and cash‑flow initiatives on shareholder value.
  • The timing advantage of the new high‑sensitivity troponin assay in point‑of‑care settings—especially with the partnership to Hisense—could unlock a significant TAM in the acute care market. Although the company has acknowledged that early U.S. launch is not imminent, the strategic focus on this assay aligns with the growing demand for rapid, accurate diagnostics in emergency departments. Even if the launch remains a mid‑term goal, the presence of a strong FDA‑cleared product provides a competitive moat that can enhance market share and pricing power over the long term. This early mover advantage in a high‑growth segment is an understated catalyst that may not yet be fully reflected in valuation.
Read more

Bear case

  • The company’s recurring free‑cash‑flow conversion remains below the 25% target, standing at 17% in 2025, a shortfall that management has attributed to ERP implementation delays and late sales collections. These timing issues, while not structural, signal ongoing operational inefficiencies that could persist if the ERP issues are not fully resolved. The need for a 2026 “midpoint” free‑cash‑flow of $140 million, with a recurring conversion of only 30%, indicates that cash‑flow challenges are likely to continue, potentially limiting the firm’s ability to fund growth or return capital to shareholders.
  • Gross margin is expected to remain flat in 2026 due to tariff impacts and negative product‑mix effects, as noted by the CFO. The company’s reliance on a mix of instrument revenue and consumables, coupled with the introduction of higher‑cost, lower‑margin point‑of‑care assays, creates a structural pressure that could erode profitability if not offset by direct procurement savings. The CFO’s acknowledgement that direct procurement initiatives are “not baked into this year” further underlines the risk that margin improvement may not materialize in the near term, leaving the company vulnerable to pricing and cost pressures.
  • Net debt to adjusted EBITDA sits at 4.2x, above the company’s target range, primarily because of cash timing on collections. Although the company projects a 3.8x leverage ratio in 2026, the current debt burden and high interest expense of approximately $200 million could squeeze earnings, especially if refinancing opportunities do not materialize or if interest rates rise. The debt profile creates a risk that the company may have to divert cash flow to interest payments rather than investing in growth or returning capital to shareholders.
  • The Lex molecular diagnostics platform, while potentially high‑margin, is currently dilutive and its commercialization timeline remains uncertain. Management has indicated that the platform’s FDA clearance is “in the final stages,” but the lack of a definitive launch date and the inherent regulatory complexities for CLIA waiver devices create a risk that the expected revenue boost may be delayed or not realized. This uncertainty, coupled with the $50–$60 million onetime outlay for Lex integration, introduces a temporary negative impact on earnings that could weigh on investor sentiment.
  • The company’s exposure to a potential national value‑based procurement (VBP) program in China could reduce revenue by 0.5%–1% if QuidelOrtho products are included. While the CFO notes that the company is awaiting details, the mere possibility of such a program introduces a geopolitical risk that could materially affect the company’s Chinese revenue stream, which is already projected to grow only at low single digits. This potential headwind is an unpriced risk that could compress margins and top‑line growth.
Read more

Business Unit Breakdown of Revenue (2025)

Long-Term Debt, Type Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 161.43 Bn 24.86 3.64 12.93 Bn
2 SYK Stryker Corp 125.09 Bn 38.55 4.98 15.86 Bn
3 MDT Medtronic plc 105.13 Bn 22.78 2.96 28.07 Bn
4 BSX Boston Scientific Corp 88.11 Bn 30.21 4.39 11.44 Bn
5 EW Edwards Lifesciences Corp 46.61 Bn 43.80 7.68 0.60 Bn
6 PHG Koninklijke Philips Nv 31.54 Bn 26.82 1.57 9.41 Bn
7 DXCM Dexcom Inc 24.43 Bn 29.12 5.24 -
8 STE STERIS plc 21.57 Bn 30.27 3.70 1.90 Bn